Your browser doesn't support javascript.
loading
Spartalizumab or placebo in combination with dabrafenib and trametinib in patients with BRAF V600-mutant melanoma: exploratory biomarker analyses from a randomized phase 3 trial (COMBI-i).
Tawbi, Hussein A; Robert, Caroline; Brase, Jan C; Gusenleitner, Daniel; Gasal, Eduard; Garrett, James; Savchenko, Alexander; Görgün, Güllü; Flaherty, Keith T; Ribas, Antoni; Dummer, Reinhard; Schadendorf, Dirk; Long, Georgina V; Nathan, Paul D; Ascierto, Paolo A.
Afiliação
  • Tawbi HA; The University of Texas MD Anderson Cancer Center, Houston, Texas, USA htawbi@mdanderson.org.
  • Robert C; Gustave Roussy, Villejuif, and Paris-Saclay University, Orsay, France.
  • Brase JC; Novartis Pharma AG, Basel, Switzerland.
  • Gusenleitner D; Novartis Institutes for BioMedical Research, Inc, Cambridge, Massachusetts, USA.
  • Gasal E; Novartis Pharmaceuticals Corporation, East Hanover, New Jersey, USA.
  • Garrett J; Novartis Pharmaceuticals Corporation, Cambridge, Massachusetts, USA.
  • Savchenko A; Novartis Pharmaceuticals Corporation, Cambridge, Massachusetts, USA.
  • Görgün G; Novartis Pharmaceuticals Corporation, Cambridge, Massachusetts, USA.
  • Flaherty KT; Dana-Farber Cancer Institute/Harvard Medical School and Massachusetts General Hospital, Boston, Massachusetts, USA.
  • Ribas A; Jonsson Comprehensive Cancer Center, University of California, Los Angeles, Los Angeles, California, USA.
  • Dummer R; University Hospital Zürich Skin Cancer Center, Zürich, Switzerland.
  • Schadendorf D; University Hospital Essen, Essen, and German Cancer Consortium, Heidelberg, Germany.
  • Long GV; Melanoma Institute Australia, The University of Sydney, and Royal North Shore and Mater Hospitals, Sydney, New South Wales, Australia.
  • Nathan PD; Mount Vernon Cancer Centre, Northwood, UK.
  • Ascierto PA; Istituto Nazionale Tumori, IRCCS, Fondazione "G. Pascale", Naples, Italy.
J Immunother Cancer ; 10(6)2022 06.
Article em En | MEDLINE | ID: mdl-35728875
Assuntos
Palavras-chave
Texto completo
Adicionar na Minha BVS
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias Cutâneas / Biomarcadores Tumorais / Melanoma Tipo de estudo: Clinical_trials / Prognostic_studies Limite: Humans Idioma: En Revista: J Immunother Cancer Ano de publicação: 2022 Tipo de documento: Article País de afiliação: Estados Unidos País de publicação: Reino Unido
Texto completo
Adicionar na Minha BVS
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias Cutâneas / Biomarcadores Tumorais / Melanoma Tipo de estudo: Clinical_trials / Prognostic_studies Limite: Humans Idioma: En Revista: J Immunother Cancer Ano de publicação: 2022 Tipo de documento: Article País de afiliação: Estados Unidos País de publicação: Reino Unido